全民健康保險藥品給付規定 / 健保碼及健保價 |
See related Aricept film-coated tab[愛憶欣 膜衣錠] information |
|
製造商 |
Eisai |
代理/經銷商 |
Eisai |
成份 |
Donepezil HCl |
適應症 |
Symptomatic treatment of mild, moderate & severe Alzheimer's disease. |
用量 |
Adult 5 mg once daily in the evening just prior to retiring. Dose may be increased to 10 mg once daily following 4-6 weeks of clinical assessment. |
過量 |
View Aricept[愛憶欣] overdosage for action to be taken in the event of an overdose. |
用法 |
May be taken with or without food |
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
禁忌 |
[Click for Aricept[愛憶欣] detailed prescribing infomation] |
注意事項 |
Sick sinus syndrome, supraventricular cardiac conduction conditions, history of ulcer disease, history of asthma or obstructive pulmonary disease, bladder outlet obstruction, seizure. Pregnancy & lactation. |
不良反應 |
Nausea, diarrhea, insomnia, vomiting, muscle cramp, fatigue & anorexia. Syncopal episodes have been reported.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
交互作用 |
Anesth, medications with anticholinergic activity, succinylcholine, other neuromuscular blockers or cholinergic agonists (e.g. bethanechol).
View more drug interactions with Aricept[愛憶欣] |
使用上注意 |
For caution against possible variation of physical aspect of medicine... click to view Aricept[愛憶欣] detailed prescribing infomation |
儲存 |
View Aricept[愛憶欣] storage conditions for details to ensure optimal shelf-life. |
描述 |
View Aricept[愛憶欣] description for details of the chemical structure and excipients (inactive components). |
作用 |
View Aricept[愛憶欣] mechanism of action for pharmacodynamics and pharmacokinetics details. |
本商品之市售規格 |
劑型 |
包裝 |
圖片 |
Aricept 膜衣錠 |
Aricept 5 mg x 28's |
 |
Aricept 10 mg x 28's |
 |
|
|
Manufacturer: |
Eisai |
Distributor: |
Eisai |
|
 |

 |
|
|